It is not necessarily the end for RXC004, as phase 2 assessments in pancreatic cancer and colorectal cancer as a monotherrapy are ongoing, and Redx is also looking at the drug in combination with ...
Back in 2017, the UK biotech RedX Pharma had to sell its prized asset ... at least until the end of phase 2. Rather than looking as LOXO-305 as the one that got away, Anson said its success ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback